Again, who's hasn't been able to get the 12U who has a real need? There's a company called FedEx that does overnight shipments.
So fraggy, do you have a prescription you're having trouble filling? Have you found any real person having trouble getting the 12U cartridges? Are you just pointing out you like to "cry wolf"?
My commercial idea froma while ago:
Camera zooms in down the table as people are getting rolls, etc. Focuses on grandma and she says "Happy Thanksgiving!" and she takes a dose of afrezza right at the table.
Bashers like you are reason enough.
INNOVATIVE! People with diabetes inject insulin escapes. This invention will make life easier
Inhaled insulin produced in the United States will be distributed worldwide thanks to an exclusive licensing agreement worth 925 million dollars, the pharmaceutical group Sanofi ended and American biotechnology company MannKind Corporation.
This product, called Afrezza, which is "a new inhaled insulin with rapid action, for the treatment of diabetes type 1 and type 2 in adults", to be released in the US in the first quarter of 2015, said the two companies in a joint statement quoted by AFP.
MannKind Corporation will receive the initial amount of 150 million dollars and then will receive installment payments that could reach a total of 775 million dollars if "special objectives in terms of development, regulatory and thresholds for sale" They will be met. In light of these subsequent payments could reach agreement as to the total amount of 925 million dollars (about 690 million euro).
United Afrezza development and marketing of the drug, Sanofi and MannKind will share losses and profits, with that percentage set out in that agreement: 65% for and 35% for MannKind Sanofi.
The Cooperation Agreement provides that the laboratory Sanofi will be responsible for the development, regulation and commercialization of the product. Under a separate agreement, MannKind Afrezza will manufacture the product in its plant in Danbury, a city in the US state of Connecticut.
"Afrezza just joined our portfolio of solutions against diabetes, which is booming. Afrezza occupies a unique place in our strategy and gives patients a new therapeutic option based on insulin, in order to rein in diabetes without requiring numerous daily injections, "said Pierre Chancel, vice president for Diabetes within the group Less